GenoTrak

Our platform is built around one of the most critical operational challenges in autologous cell therapy: protecting scarce and high-value manufacturing slots. By bringing visibility to slot readiness and upstream dependencies, the platform helps sponsors reduce preventable slot loss, avoid costly disruptions, and improve manufacturing-capacity utilization.

Rather than simply tracking workflow steps, the platform continuously aligns critical readiness conditions such as patient eligibility, apheresis scheduling, collection-center capacity, courier readiness, and manufacturing acceptance. This ensures that every case is managed based on true operational readiness, not just task completion.

The platform is designed to identify delays, bottlenecks, and readiness failures before they escalate into missed manufacturing opportunities. With built-in alerts, escalations, and exception workflows, teams can intervene early, resolve issues faster, and keep therapies moving forward with greater confidence.

Cell therapy execution depends on multiple external and internal stakeholders. Our platform gives sponsors a unified operational view across physicians, apheresis teams, logistics providers, labs, contract manufacturers, and case managers—creating a single source of truth for therapy execution across the network.

This is more than a tracking system. The platform drives action by triggering tasks, coordinating milestones, and guiding next steps for each stakeholder. That means teams spend less time chasing updates manually and more time managing the cases that need attention most.

Autologous therapies are not standard supply-chain workflows—they are patient-specific, time-sensitive, and operationally complex. Our platform is purpose-built for this environment, enabling precise coordination around each individual patient journey while preserving visibility, traceability, and control.